All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies-Reference-Cited by-同舟云学术

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

Published:2022-01-12 Issue: Volume: Page:1-13
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Lodise Thomas P.¹,Bassetti Matteo²,Ferrer Ricard³^ORCID,Naas Thierry⁴^ORCID,Niki Yoshihito⁵,Paterson David L.⁶,Zeitlinger Markus⁷,Echols Roger⁸

Affiliation:

1. Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA

2. Infectious Diseases Clinic, Department of Health Science, University of Genova and Policlinico San Martino IRCCS Hospital, Genova, Italy

3. Department of Intensive Care, Hospital Universitari Vall d’Hebron, Barcelona, Spain

4. Hôpital Bicetre, Bacteriology-Hygiene Unit, APHP-, University Paris-Saclay, Paris, France

5. Division of Clinical Infectious Diseases, Showa University, Tokyo, Japan

6. UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Australia

7. Department of Clinical Pharmacology, Medical University, Vienna, Austria

8. Infectious Disease Drug Development Consulting, LLC, Easton, CT, USA

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Microbiology (medical),Microbiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2022.2020099

Reference60 articles.

1. WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017 [cited 2020 Mar 2]. Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf

2. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

3. Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence

4. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

5. The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis;BMC Infectious Diseases;2024-09-13

2. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09

3. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy;Antimicrobial Resistance & Infection Control;2024-08-26

4. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

5. Development and validation of a prognostic nomogram to predict 30-day all-cause mortality in patients with CRO infection treated with colistin sulfate;Frontiers in Pharmacology;2024-07-17